Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B

Background Pleurodesis is the standard of care for non‐small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsuccessful MPE control are unable to receive effective...

Full description

Bibliographic Details
Main Authors: Rintaro Noro, Kunihiko Kobayashi, Jiro Usuki, Makiko Yomota, Masaru Nishitsuji, Tsuneo Shimokawa, Masahiro Ando, Mitsunori Hino, Koichi Hagiwara, Akihiko Miyanaga, Masahiro Seike, Kaoru Kubota, Akihiko Gemma, North East Japan Study group
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Thoracic Cancer
Subjects:
Bevacizumab plus chemotherapy
non‐small cell lung cancer
unsuccessful management of malignant pleural effusion
vascular endothelial growth factor
Online Access:https://doi.org/10.1111/1759-7714.13472

Internet

https://doi.org/10.1111/1759-7714.13472

Similar Items